Aurora Cannabis (ACB, Financial) shares experienced a significant decline, dropping 5.08%. The stock is currently trading at $5.79 per share with a trading volume of 1.65758 million shares and a turnover rate of 3.03%. The stock's price amplitude has reached 8.20%.
Recent financial reports reveal Aurora's revenue at $60.98 million, with a net profit of $4.54 million. The earnings per share stand at $0.09, though the company reports a gross loss of $3.68 million, resulting in a price-to-earnings ratio of -12.66. In terms of analyst recommendations, 17% of the six institutions providing ratings suggest buying, whereas 83% recommend holding. None advocate for selling the stock.
Within the pharmaceutical sector, where Aurora Cannabis is positioned, the average decline was 0.77%. Noteworthy performers include Cyclo Therapeutics, Biofrontera, and Quantum Biopharma, with Quantum Biopharma and its peers showing significant trading activity and fluctuations. Quantum Biopharma, Painreform, and Canopy Growth are particularly active, with turnover rates of 17.76%, 16.63%, and 10.92%, and high volatility recorded for Cyclo Therapeutics, Quantum Biopharma, and Citius Oncology.
Aurora Cannabis, headquartered in Edmonton, Canada, specializes in cultivating and selling medicinal and recreational cannabis through brands like Aurora, CanniMed, and MedReleaf. While primarily operating in Canada, the company has expanded globally, exporting medical cannabis across 20+ countries.
